TSCIP worked case · PDS0301

From a recurring evidence gap to a milestone-linked strategic outcome.

PDS0301 illustrates the public-facing TSCIP logic: synthesize the strategic uncertainty, define a decision-grade evidence path, and align development and capital with the next value inflection.

The strategic problem was tested in the field.

TSCIP did not rely on a desk-based inference. Through direct BD engagement with relevant counterparties, de-identified feedback repeatedly converged on the need for greater clarity regarding PDS0301's independent contribution to observed combination activity before a larger strategic commitment could be underwritten.

The TSCIP reframing

The recurring field feedback was converted from separate buyer interactions into a bounded evidence gate, development action and capital-to-inflection thesis.

The evidence-to-decision sequence.

1 · Synthesize the recurring requirement

Direct buyer engagement showed that the contribution question was a recurring strategic decision requirement rather than a generic request for "more data."

2 · Define a bounded next step

The development path was reframed around a specific late-stage evidence milestone capable of changing the strategic discussion.

3 · Align capital with the inflection

The financing requirement was organized around reaching that milestone rather than simply extending operating runway.

4 · Re-enter the strategic process

TSCIP could then re-engage mapped counterparties around a more explicit evidence, development and transaction thesis rather than simply returning with additional data.

Separately verifiable public outcome.

August 11, 2026PDS Biotech publicly announced a strategic refocus prioritizing PDS0301 in metastatic colorectal cancer and a partnership strategy for PDS0101.
September 8, 2026PDS Biotech announced a PIPE led by Nant Capital with total potential proceeds initially described as up to $22.55 million, including a milestone closing tied to submission of a registrational Phase 3 protocol for PDS0301.
September 14, 2026PDS Biotech announced the initial closing, generating approximately $11.3 million in gross proceeds. The remaining milestone closing is $11 million, bringing total potential proceeds to approximately $22.3 million. Dr. Patrick Soon-Shiong and James Banaag joined the board, and NantWorks received a one-year exclusive right to negotiate an exclusive license to PDS0101.

Important distinction.

PDS Biotech's public announcements do not attribute the financing or board appointments to TSCIP. The description of TSCIP's role on this page reflects the TSCIP engagement and is presented to illustrate the TSCIP workflow. It should not be read as a claim that TSCIP was the sole cause of the financing or other publicly announced transactions.